store at low temperature
store at -80°C
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody targeting the CD70 antibody. Vorsetuzumab has anticancer activity and can enhance the macrophage-associated phagocytosis of kidney cancer cells and inhibit Burkitt lymphoma.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 247.00 | |
5 mg | In stock | $ 747.00 | |
10 mg | In stock | $ 1,180.00 |
Description | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a monoclonal antibody targeting the CD70 antibody. Vorsetuzumab has anticancer activity and can enhance the macrophage-associated phagocytosis of kidney cancer cells and inhibit Burkitt lymphoma. |
In vitro |
In vitro, vorsetuzumab (10 μg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells[1]. Vorsetuzumab (10 μg/mL; 2 h) can be developed into a bispecific anti-human CD70/KWAR23 antibody. The results show that KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1)[1]. |
In vivo | In SRG mice, vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits the growth of Burkitt’s lymphoma cells[1]. |
Synonyms | SGN-70 |
Molecular Weight | N/A |
CAS No. | 1165740-62-4 |
store at low temperature
store at -80°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vorsetuzumab 1165740-62-4 Immunology/Inflammation Immunology/Inflammation related SGN70 SGN 70 SGN-70 inhibitor inhibit